The Patient - Patient-Centered Outcomes Research

, Volume 10, Issue 5, pp 643–651 | Cite as

Patient Preferences for Pain Management in Advanced Cancer: Results from a Discrete Choice Experiment

  • David M. Meads
  • John L. O’Dwyer
  • Claire T. Hulme
  • Phani Chintakayala
  • Karen Vinall-Collier
  • Michael I. Bennett
Original Research Article

Abstract

Background

Pain from advanced cancer remains prevalent, severe and often under-treated.

Aim

The aim of this study was to conduct a discrete choice experiment with patients to understand their preferences for pain management services and inform service development.

Methods

Focus groups were used to develop the attributes and levels of the discrete choice experiment. The attributes were: waiting time, type of healthcare professional, out-of-pocket costs, side-effect control, quality of communication, quality of information and pain control. Patients completed the discrete choice experiment along with clinical and health-related quality of life questions. Conditional and mixed logit models were used to analyse the data.

Results

Patients with cancer pain (n = 221) and within palliative care services completed the survey (45% were female, mean age 64.6 years; age range 21–92 years). The most important aspects of pain management were: good pain control, zero out-of-pocket costs and good side-effect control. Poor or moderate pain control and £30 costs drew the highest negative preferences. Respondents preferred control of side effects and provision of better information and communication, over access to certain healthcare professionals. Those with lower health-related quality of life were less willing to wait for treatment and willing to incur higher costs. The presence of a carer influenced preferences.

Conclusions

Outcome attributes were more important than process attributes but the latter were still valued. Thus, supporting self-management, for example by providing better information on pain may be a worthwhile endeavour. However, service provision may need to account for individual characteristics given the heterogeneity in preferences.

Keywords

Pain Management Pain Control Cancer Pain Discrete Choice Experiment Palliative Care Service 

Notes

Acknowledgements

The authors thank the centres and patients who participated in the study—without their efforts the study would not have been possible. We also thank Lucy Ziegler who helped prepare the ethics application for the focus groups and helped run one of the groups; and Joachim Marti who gave advice on the analysis. This report presents independent research commissioned by the National Institute for Health Research under its Programme Grants for Applied Research programme [Improving the Management of Pain from Advanced Cancer in the Community (IMPACCT) RP-PG-0610-10114]. The views expressed in this report are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health.

Author contributions

DMM designed the study, analysed the data and wrote the manuscript. JLO’D helped design the study, write the protocol, was involved in the generation, testing and refinement of the survey, and managed the data collection. CTH was involved in the study design and interpretation of results. PC provided guidance on the survey design, analysis and interpretation. KV-C helped with the ethics application, conducted the qualitative analysis and helped with site co-ordination. MIB assisted with the survey design and set-up, provided clinical input, helped interpret the results and write the paper.

Compliance with Ethical Standards

Conflict of interest

David M. Meads, John L. O’Dwyer, Phani Chintakayala, Karen Vinall-Collier and Claire T. Hulme have no conflicts of interests directly relevant to the content of this study. Michael I. Bennett has no financial interests to declare but has conducted research that aims to improve the self-management of symptoms in the community.

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Supplementary material

40271_2017_236_MOESM1_ESM.doc (44 kb)
Supplementary material 1 (DOC 44 kb)
40271_2017_236_MOESM2_ESM.doc (34 kb)
Supplementary material 2 (DOC 34 kb)
40271_2017_236_MOESM3_ESM.doc (42 kb)
Supplementary material 3 (DOC 42 kb)

References

  1. 1.
    Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20(8):1420–33.CrossRefPubMedGoogle Scholar
  2. 2.
    Fisch MJ, Lee J-W, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol. 2012;30(16):1980–8.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Van den Beuken-van Everdingen M, De Rijke J, Kessels A, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18(9):1437–49.CrossRefGoogle Scholar
  4. 4.
    Shi Q, Smith TG, Michonski JD, et al. Symptom burden in cancer survivors 1 year after diagnosis. Cancer. 2011;117(12):2779–90.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999;353(9165):1695–700.CrossRefPubMedGoogle Scholar
  6. 6.
    Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3(1):38–44.CrossRefPubMedGoogle Scholar
  7. 7.
    Gomes B, Higginson I, Calanzani N, et al. Preferences for place of death if faced with advanced cancer: a population survey in England, Flanders, Germany, Italy, the Netherlands, Portugal and Spain. Ann Oncol. 2012;23(8):2006–15.CrossRefPubMedGoogle Scholar
  8. 8.
    Department of Health. End of life care strategy: promoting high quality care for all adults at the end of life. London: DH Publications Orderline; 2008.Google Scholar
  9. 9.
    Adam R, Wassell P, Murchie P. Why do patients with cancer access out-of-hours primary care? A retrospective study. Br J Gen Pract. 2014;64(619):e99–104.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Faculty of Medicine and Health, University of Leeds. What is the IMPACCT programme? http://medhealth.leeds.ac.uk/info/655/impacct/907/what_is_the_impacct_programme. Accessed 1 Apr 2015.
  11. 11.
    Campbell NC, Murray E, Darbyshire J, et al. Designing and evaluating complex interventions to improve health care. BMJ. 2007;334(7591):455–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bate P, Robert G. Experience-based design: from redesigning the system around the patient to co-designing services with the patient. Qual Saf Health Care. 2006;15(5):307–10.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    de Bekker-Grob EW, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21(2):145–72.CrossRefPubMedGoogle Scholar
  14. 14.
    Clark MD, Determann D, Petrou S, et al. Discrete choice experiments in health economics: a review of the literature. Pharmacoeconomics. 2014;32(9):883–902.CrossRefPubMedGoogle Scholar
  15. 15.
    Ryan M, Gerard K, Amaya-Amaya M. Using discrete choice experiments to value health and health care. Dordrecht: Springer; 2007.Google Scholar
  16. 16.
    Molassiotis A, Emsley R, Ashcroft D, et al. Applying best-worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer. Lung Cancer. 2012;77(1):199–204.CrossRefPubMedGoogle Scholar
  17. 17.
    Mühlbacher AC, Junker U, Juhnke C, et al. Chronic pain patients’ treatment preferences: a discrete-choice experiment. Eur J Health Econ. 2015;16(6):613–28.CrossRefPubMedGoogle Scholar
  18. 18.
    Chancellor J, Martin M, Liedgens H, et al. Stated preferences of physicians and chronic pain sufferers in the use of classic strong opioids. Value Health. 2012;15(1):106–17.CrossRefPubMedGoogle Scholar
  19. 19.
    Gregorian RS, Gasik A, Kwong WJ, et al. Importance of side effects in opioid treatment: a trade-off analysis with patients and physicians. J Pain. 2010;11(11):1095–108.CrossRefPubMedGoogle Scholar
  20. 20.
    Meghani SH, Chittams J, Hanlon AL, Curry J. Measuring preferences for analgesic treatment for cancer pain: how do African–Americans and Whites perform on choice-based conjoint (CBC) analysis experiments? BMC Med Inform Decis Mak. 2013;13(1):118.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015;8(5):373–84.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Coast J, Al-Janabi H, Sutton EJ, et al. Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ. 2012;21(6):730–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Clarke V, Braun V. Thematic analysis. In: Teo T, editor. Encyclopedia of critical psychology. New York: Springer; 2014. p. 1947–52.CrossRefGoogle Scholar
  24. 24.
    Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72.CrossRefPubMedGoogle Scholar
  25. 25.
    Bech M, Gyrd-Hansen D. Effects coding in discrete choice experiments. Health Econ. 2005;14(10):1079–83.CrossRefPubMedGoogle Scholar
  26. 26.
    Payne K, McAllister M, Davies LM. Valuing the economic benefits of complex interventions: when maximising health is not sufficient. Health Econ. 2013;22(3):258–71.CrossRefPubMedGoogle Scholar
  27. 27.
    Brennan VK, Dixon S. Incorporating process utility into quality adjusted life years: a systematic review of empirical studies. Pharmacoeconomics. 2013;31(8):677–91.CrossRefPubMedGoogle Scholar
  28. 28.
    Loomis J. What’s to know about hypothetical bias in stated preference valuation studies? J Econ Surv. 2011;25(2):363–70.CrossRefGoogle Scholar
  29. 29.
    Brazier JE, Dixon S, Ratcliffe J. The role of patient preferences in cost-effectiveness analysis. Pharmacoeconomics. 2009;27(9):705–12.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • David M. Meads
    • 1
  • John L. O’Dwyer
    • 1
  • Claire T. Hulme
    • 1
  • Phani Chintakayala
    • 2
  • Karen Vinall-Collier
    • 1
    • 3
  • Michael I. Bennett
    • 4
  1. 1.Academic Unit of Health Economics, Leeds Institute of Health SciencesUniversity of LeedsLeedsUK
  2. 2.Leeds University Business School and Leeds Institute for Data AnalyticsUniversity of LeedsLeedsUK
  3. 3.School of DentistryUniversity of LeedsLeedsUK
  4. 4.Academic Unit of Palliative Care, Leeds Institute of Health SciencesUniversity of LeedsLeedsUK

Personalised recommendations